Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (875)	3/20/2000 4:20:00 PM
From: LLCF	Respond to of 52153

Yea don't remind us of this part: <Coulter Pharmaceutical has already completed Phase III testing of its Bexxar drug and is now preparing to file for U.S. Food and Drug Administration approval.> I'm surprised the stock isn't in the low 20's again with this sell off. Shorts must be holding it up. When are they going to file this thing???? DAK

To: Jim Oravetz who wrote (875)	3/24/2000 4:15:00 PM
From: Jim Oravetz	Read Replies (3) \| Respond to of 52153

From todays WSJEuropean Focus:Oxford GlycoSciences When analyzing a biotechnology stock, it is best to take cues from the lawyers who write prospectuses. That is, before you know virtually anything about the business, you have to hear about the risks. So if we are going to talk about Oxford GlycoSciences, a British company whose activities include protein research and the development of drugs to combat enzyme disorders, it's only proper to start with what could go wrong. After that's covered, we can move on to what can go right. Because in an industry of mostly overvalued and hyped companies, OGS has the potential to thrive. Oxford GlycoSciences trades at a market capitalization of more than GBP 700 million (1.15 billion euros) and has no product revenue and, of course, no earnings. There's little prospect for earnings in the next couple of years, either; the company lost GBP 9.7 million last year. SNIP.... ....And then there is the other, perhaps more important, leg of the OGS story: the proteomics platform. Proteomics is a spin-off science of genomics, something that has been making investors' hearts flutter of late. The 100,000 to 140,000 genes in the human genome have the ability to create perhaps as many as a million different proteins - or more. Proteins build and maintain the body and its functions. Proteomics is the attempt to figure out which proteins do what in bodies both healthy and diseased. This science is one of the keys to the biotechnology revolution, because many new drugs are proteins or target proteins. OGS is out in front, say investors. "It's very complicated and time-consuming. Nobody but OGS has got the capability," says the New York money manager, adding, "It's the definitive proteomics platform, at a cheap price relative to the other genomics companies." The company has formed a joint venture with the American genomics-database company Incyte Therapeutics. Also, three big pharmaceutical companies are collaborating with OGS, including Bayer, Pfizer and Merck. The Merck deal, signed in December, is of particular interest. It's a largely exploratory deal, but Merck doesn't often look outside for research help. Mr. Kranda, the CEO, says by the end of the year the company will have filed patents on 1,500 different proteins and their effects in various diseases, information that will go into its database. Do these have any value? We'll have to see. But where there's risk, there can be reward. THE END. Who are these investors that have so much insite? Jim